When the active ingredient is not supposed to be released in the stomach, a formulator will design his dosage form with an enteric release profile. BASFs enteric release excipients offer maximum functionality while being the most easy-to-apply.
Functional solutions for formulations with enteric drug release
With an enteric release profile, the drug release of the drug is delayed until the dosage form reaches the intestine. This release characteristic is typically chosen either to protect the stomach from a drug (i.e. acetylsalicylic acid), or to protect a sensitive drug from the acids in the stomach (i.e. most proton pump inhibitors). Enteric release profiles are also used for omega-3 softgel capsules in order to prevent dissolution of the capsules in the stomach, potentially leading to unpleasant burps. And in combination with effective sustained release excipients like Kollicoat® SR 30 D, enteric release polymers can also be used for delayed sustained drug release starting only in the intestine.
BASF offers the most widely used functional excipient for enteric release profiles in both aqueous and powderous form. Either one of them offers simple processing and reliable functional results.